NANO-VESICLES OF SALBUTAMOL SULPHATE IN METERED DOSE INHALERS: FORMULATION, CHARACTERIZATION AND IN VITRO EVALUATION
Objective: The present work was aimed to prepare niosomes entrapping salbutamol sulphate (SS) using reversed phase evaporation method (REV).
Methods: Niosomes were prepared by mixing span 60 and cholesterol in 1:1 molar ratio in chloroform, SS in water was then added to organic phase to form niosomal SS. Formulations after evaporation of chloroform, freeze centrifuged then lyophilized, were evaluated for particles size, polydispersity index (Pdi), zeta-potential, morphology, entrapment efficiency (EE%) and in vitro release. For pulmonary delivery; metered dose inhalers (MDI) were prepared by suspending SS niosomes equivalent to 20 mg SS in hydrofluoroalkane (HFA). The metered valve was investigated for leakage rate, the total number of puffs/canister, weight/puff, dose uniformity and particle size.
Results: The results showed spherical niosomes with 400-451 nm particles that entrapped 66.19% of SS. 76.54Â±0.132% SS release from niosomes that showed a controlled release profile for 8h. The leakage test was not exceeding 4 mg/3 d, the number of puffs were up to 200puffs/canister, the dose delivered/puff was 0.1 mg and 0.64-4.51Î¼m niosomal aerosol.
Conclusion: The results indicate an encouraging strategy to formulate a controlled drug delivery by entrapping (SS) in niosomes which could be packaged into (MDI) that met the requirements of (USP) aerosols guidelines which offering a novel approach to respiratory delivery.
2. Kaparissides C, Alexandridou S, Kotti K, Chaitidou S. Recent advances in novel drug delivery systems. J Nanotechnol 2006;2:1-11.
3. Wall DA. Pulmonary absorption of peptides and proteins. Drug Delivery 1995;2:1-20.
4. Anselmo AC, Mitragotri S. An overview of the clinical and commercial impact of drug delivery systems. J Controlled Release 2014;190:15-28.
5. Taburet AM, Schmit B. Pharmacokinetic optimization of asthma treatment. Clin Pharmacokinetics 1994;26:396-418.
6. El-najjar BY, Hussain SA. Chitosan microspheres for the delivery of chemotherapeutic agents: paclitaxel as a model. Asian J Pharm Clin Res 2017;10:15-9.
7. Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, et al. Niosomes from 80s to present: the state of the art. Adv Colloid Interface Sci 2014;205:187-206.
8. Duarah S, Pujari K, Durai RD, Narayanan VHB. Nanotechnology-based cosmeceuticals: a review. Int J Appl Pharm 2016;8:8-12.
9. Morgan D, Paull J, Richmond B, Wilsonâ€Evered E, Ziccone S. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986;22:587-93.
10. Moxham J, Costello JF. Textbook of medicine. ed. Souhami RL, Moxham J. 506 (Chapter 15), (3rd ed., Churchill Livingstone, London, 1997); 1997.
11. Hutchings M, Paull J, Wilsonâ€Evered E, Morgan D. Pharmacokinetics and metabolism of salbutamol in premature labour. Br J Clin Pharmacol 1987;24:69-75.
12. Hua W, Liu T. Preparation and properties of highly stable innocuous niosome in Span 80/PEG 400/H2O system. Colloids Surf A 2007;302:377-82.
13. Szoka JF, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 1987;75:4194-8.
14. Abd-Elbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm 2008;357:189-98.
15. Fonte P, Soares S, Sousa F, Costa A, Seabra V, Reis S, et al. Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin-loaded into PLGA nanoparticles. Biomacromolecules 2014;15:3753-65.
16. Arafa MG, Ayoub BM. DOE optimization of the nano-based carrier of pregabalin as hydrogel: new therapeutic and chemometric approach for controlled drug delivery systems. Sci Rep 2017;7:41503.
17. Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci 2002;251:360-5.
18. Glavas-Dodov M, Goracinova K, Mladenovska K, Fredro-Kumbaradzi E. Release profile of lidocaine HCl from topical liposomal gel formulation. Int J Pharm 2002;242:381-4.
19. Gursoym A, Kut E, Ozkirmli S. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of the liposome by derivative spectroscopy. Int J Pharm 2004;271:115â€“23.
20. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983;15:25-35.
21. Kulkarni A, Mandhare T, Aloorkar N. Application of novel natural polymer for controlling the release of fenoverine from controlled release matrix tablets. Int J Appl Pharm 2017;9:1-9.
22. De-Boer AH, Le Brun PPH, Van Der Woude HG, Hagedoorn P, Heijerman HGM, Frijlink HW. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as a de-agglomeration principle. Eur J Pharm Biopharm 2002;54:17-24.
23. Jones SA, Martin GP, Brown MB. High-pressure aerosol suspensions-a novel laser diffraction particle sizing system for hydrofluroalkane pressurized metered dose inhalers. Int J Pharm 2005;302:154-65.
24. Marie PF, Pierre L, Anne G. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. Int J Pharm 2004;275:201-9.
25. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Controlled Release 2014;185:22-36.
26. Bendas ER, Abdullah H, El-Komy MHM, Kassem MAA. Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus. Int J Pharm 2013;458:287-95.
27. Jassem NA, Rajab NA. Fomulation and invitro evaluation of azilsartan medoxomil nanosuspension. Int J Pharm Pharm Sci 2017;9:110-9.
28. Parker A, Miles K, Cheng K, Huang J. Lateral distribution of cholesterol in dioleoylphosphatidylcholine lipid bilayers: cholesterolâ€“phospholipid interactions at high cholesterol limit. Biophys J 2004;86:1532-44.
29. Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003;255:175-87.
30. Hanif SN, Garcia-Contreras L. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbial 2012;2:118-24.
31. Glyn T, Ian K. Pulmonary drug delivery, chapter 10 in drug delivery and targeting. Anya MH, Andrew WL, James S. ed. Taylor and Francis, Inc, New York; 2001.
32. US Pharmacopeial Convention 27, Rockville, MD; 2004. p. 2253-8.